News

Purple Biotech announces publication of study on potential of NT219
Purple Biotech (PPBT) announced the publication of an independent study titled “IRS2 as a driver of brain metastasis in colorectal cancer: a ...
Nasdaq7d
Purple Biotech Discovers Potential of NT219 and 5-FU Combination Therapy in Inhibiting Brain Metastasis of Colorectal Cancer
Purple Biotech Ltd. announced a significant study revealing that their drug NT219, combined with 5-fluorouracil (5-FU), effectively inhibits colorectal cancer brain metastasis by targeting the ...
GlobalData on MSN2mon
Purple Biotech advances NT219 into Phase II recurrent/metastatic SCCHN study
Purple Biotech has entered a Phase II trial with its small molecule drug, NT219, focusing on patients with ...
Yahoo Finance26d
Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company's oncology ...
The Bakersfield Californian26d
Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American ...
REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that ...